Ness just out
Lpath Initiates First-in-Human Dosing in Phase 1 Clinical Trial of Lpathomab
PR Newswire Lpath, Inc.
17 minutes ago
SAN DIEGO, Sept. 15, 2015 /PRNewswire/ -- Lpath, Inc. (LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that the first cohort of six subjects has been dosed in the Phase 1 clinical trial with LpathomabTM. The double-blind, placebo-controlled, single ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Lpathomab in healthy volunteers. The trial also aims to establish a maximum tolerated dose for future clinical studies in patients with neuropathic pain. The trial will include a total of five cohorts at increasing doses.
Dario Paggiarino, M.D., Lpath's senior vice president, chief development officer said, "The dosing of our first subjects with Lpathomab is a significant milestone and we are very pleased to begin the development of this important product candidate intended to treat neuropathic pain, which is an area of tremendous unmet medical need."
Lpathomab is an antibody targeting lysophosphatidic acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy. Other preclinical studies have also demonstrated the potential for Lpathomab as a treatment for traumatic brain injury.
Cash and cash equivalents at end of period increased to $542,835 from $327,298
In a nutshell, improvements in all fronts: Gross margins, loss, cash/cash equivalents, stockholders equity......
Excellent performance by new management team.....Congrats!!
We go at least to $3.5 tomorrow on very high volune
AVXL will plummet like TTPH did on poor results
It looks like I am not the only one
The wristband also separated on one end. It happened even though I am gentle with this device and never get it wet. Dis anyone have problems like this? Does the company do anything about it?
Is earnings in the pre market of after market? thank you
Play their game....accumulate at these prices
DRAM $1.25 with 2M share float Will Report Strong Earnings September 14 (Per reiterated guidance) - Will triple in a hurry - 0.1 X Sales
Dragonwire (DRWI) is a leading global supplier of packet microwave radio systems for mobile and access networks. Yesterday the company was granted an additional 180 days to regain compliance with the minimum $1.00 bid price per share requirement. The new extension period runs through February 29, 2016
August 4 Update:
We have entered an agreement with Nokia to address the impact of reduced demand being experienced through this channel in the first half of FY16 including temporary cash flow measures as well as a new commercial arrangement for Support and Maintenance services.
"We are pleased that we could come to these updated arrangements with Nokia. Nokia continues to be an important part of our business and we appreciate the support" said Peter Allen, DragonWave President and CEO.
Further expense reduction actions
We also confirmed that we are implementing further cost saving measures to reduce expenses and associated cash consumption.
The cost savings measures being implemented are planned to save approximately US$8 million in annual operating expenses as a result of staff reductions and other measures. We expect operating expenses going forward starting in our third quarter to be approximately US$8.5 million per quarter. The full impact on the financial statements will be discussed on our next earnings call. Peter Allen, DragonWave's President and CEO, said "These measures will reduce our break-even point and conserve cash going forward."
Status of major carrier activity - production and deployment
In our last conference call we talked about receiving our first order from a North America Tier 1 operator for small cell backhaul. We are now seeing the funnel with this operator strengthening.
We have been deploying equipment into our first major customer in India since May 2014.This customer has continued to place follow on orders and the rollouts are proceeding vigorously.
In May this year we announced that we had received orders to supply a second Tier 1 operator in India. During the deployment phase we have experienced an unexpected problem with our product. The problem has been isolated and corrective actions are being implemented. The deployment is time sensitive and has been halted. We are developing a plan to manage the cash flow impact and also working with the customer on the path forward.
Having successfully completed a lab trial with Harmony Enhanced we are now moving to a field trial with a European based global carrier.
Q2 FY16 revenue expectations
We are updating our revenue expectations for the second quarter of fiscal year 2016. On our Q1 earnings call we indicated we anticipated revenue growth of between 30% and 60% in Q2 relative to Q1. We believe we will be within this guidance but at the lower end of the range given lower revenue than expected from India.
We are doomed here for at least 3 more weeks
You are right, I compared AVNW with AAPL, NFLX, TWTR, NFLX, BABA, TSLA, and FB and the 1-month chart shows that only AVNW's pps increased 5% compared to losses ranging from 5 to 20% for the bloated I've compared it with.
This means that undervalued microcap companies like AVNW have not been included in the most recent bull market because everyone was chasing the blue-chip macrocaps mentioned above inflating their pps to unsustainable levels. Smart value investors will have to be more selective and find gems like AVNW, WSTL, CRNT, and the like, where there is real upside going forward.
Rumours flying that CommScope and others are after Westell because it's so cheap but primarily for its new products....specially those to overcome the near-far issue inside buildings.
Excellent DD on this undervalued gem. Rumours flying that CommScope and others are after Westell because it's so cheap but primarily for its new products....specially those to overcome the near-far issue inside buildings.
That's a nice investment in my book
This one does not have the toxic financing that our beloved AEZS does but it has a couple of clinical failures.....although the results for ASONEP, a Renal cell carcinoma (RCC) drug candidate, were very encouraging. In fact, there are still 6 patients on the drug for several months after the trial ended. RCC is very aggressive and tough to treat...Sutent is a horrible and ineffective RCC drug selling billion a year. I expect a new look at this potentially blockbuster drug with a partner